Vanderbilt University Medical Center | Strategic Alliance Partners

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

“Our study offers molecular and cellular insights into this aggressive subtype of prostate cancer, which we hope will ultimately impact patient care,” said the study’s lead author, Hong Yuen Wong, PhD.

"In the office, absolutely, I should be called by my profession," says one urologist.

“The rates of testing declined slightly, about 2 absolute percentage points, over the study interval, despite the introduction of guidelines recommending it during the study period,” says Ryan Hsi, MD, FACS.

Jeffrey Tosoian, MD, MPH, recaps recent updates from the TheraP, ARAMIS, TITAN, ARASENS, and ATLAS prostate cancer trials.

The researchers assessed gender differences in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.

“The benefit of the clinic is a holistic approach to the survivorship care that takes into account things that we as urologists don’t usually consider in our everyday patient encounters,” said Niels Johnsen, MD, MPH, assistant professor of Urology, Division of Reconstructive Urology and Pelvic Health, Vanderbilt University Medical Center.

“Health care disparities are very complex issues; it’s not like a linear cause-and-effect relationship,” says Elisabeth M. Sebesta, MD.

“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.

Amy N. Luckenbaugh, MD, recaps 5 presentations from the 2022 American Society of Clinical Oncology Annual Meeting.

"Now with FDA approval, patients will have much improved ability to use this efficacious therapy on a long-term basis, which is most beneficial for them," Roger R. Dmochowski, MD, MMHC.

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Tosoian is developing the Contemporary Uro-oncologic specimens and Protocols (CUSP) program, which will implement prospective collection of the biospecimens and correlative clinical data essential to basic, translational, and clinical genitourinary cancer research.

“I think we are good at treating the cancer but maybe not great at treating the patient as a whole. And that is an area that we can improve going forward based on research like this,” says Amy N. Luckenbaugh, MD.

“We kind of expected that treatment type wouldn't make a ton of difference in terms of…mental health outcomes after either surgery or radiation…but we were very clearly able to find groups of people who were at risk for poor mental health outcomes,” says Amy N. Luckenbaugh, MD.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

"There have been few therapies that have so galvanized management of a urologic condition as what we've witnessed over the past decade regarding the use of onabotulinumtoxinA (Botox) for bladder dysfunction," says Melissa R. Kaufman, MD, PhD, FACS.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence.

"The newest frontier of therapy for stress incontinence is regenerative medicine and stem cell–based therapies," says Melissa R. Kaufman, MD, PhD, FACS.

In this interview, Kelvin A. Moses, MD, PhD, FACS, provides insight on how clinicians may be able to help patients with prostate cancer address the financial burden of the disease.

“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.

"I'm hopeful and optimistic that over the next couple of years, we have some really reliable biomarkers to utilize in these patients who we know have frequent recurrences,"says Kristen Scarpato, MD, MPH.

“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.

“We need to be aware of what patients are having to pay out of pocket, how it can impact their overall quality of life, [and] how can it impact their ability to pay for other necessities in life,” says Kelvin A. Moses, MD, PhD, FACS.